Risk factors

THE CDC'S ACIP RECOMMENDS PREVNAR 13® (PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE [DIPHTHERIA CRM197 PROTEIN]) FOR IMMUNOCOMPROMISED ADULTS AGED ≥19 AND FOR IMMUNOCOMPETENT ADULTS AGED ≥65 BASED ON SHARED CLINICAL DECISION-MAKING1

Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is a vaccine approved for adults 18 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine. Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication.

Age is not the only risk factor: A wide range of conditions can make patients more vulnerable to pneumococcal pneumonia

Pneumococcal pneumonia risk rates vs healthy 18- to 64-year-olds2*†

** This is an optional area where footnotes can live.

HIV=human immunodeficiency virus.

  • The CDC’s ACIP recommends Prevnar 13® for immunocompetent adults aged 65 and older based on the shared clinical decision-making of the provider and patient, as well as adults aged 19 and older with certain immunocompromising conditions,§ functional or anatomic asplenia,| | CSF leaks, and cochlear implants
  • There is no Prevnar 13® recommendation for immunocompetent adults aged 19-64 with certain chronic conditions, including chronic heart disease, chronic lung disease, diabetes mellitus, alcoholism, chronic liver disease, in addition to current smokers; the CDC’s ACIP has not formally evaluated this policy question3,4

Patient profiles

Learn more about adult patients who may be appropriate candidates for vaccination with Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])

View patient profiles

   *Data from a retrospective cohort study from 3 large, longitudinal, US healthcare databases of medical and outpatient pharmacy claims from 2007-2010.2

    †Risk ratios were calculated using rates of pneumococcal pneumonia among healthy adults aged 18-64 as a baseline (17.6 cases per 100,000 person-years).2

    ‡Defined as malignant neoplasms or solid organ transplantations associated with immunosuppressive agents or radiation therapy.2

    §Congenital or acquired immunodeficiencies, HIV, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, iatrogenic immunosuppression (diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy), solid organ transplant, multiple myeloma.3

    ||​​​​​​​Including sickle cell disease/other hemoglobinopathies and congenital or acquired asplenia.3

Efficacy & Safety

  • Risk factors
  • Proven efficacy & safety
  • Immunogenicity & safety

Order Prevnar 13®

Order vaccines directly through Pfizer's online ordering system

Order now

References:
  1. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:1069-1075. doi: http://dx.doi.org/10.15585/mmwr.mm6846a5.
  2. Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102-1106.
  3. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.
  4. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1-9. doi:10.1093/ofid/ofu024.

Indication

  • In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine
  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • In adults, the most commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of this site.

Please see full Prescribing Information for Prevnar 13®.

  • In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine